Utah Medical Products, Inc.
Description
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
About
CEO
Mr. Kevin L. Cornwell
Employees
169
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Instruments & Supplies
MIC code
XNGS
Address
7043 South 300 West, Midvale, UT 84047-1048, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Jan 26, 2026 | — | — | — | — |
| Oct 27, 2025 | — | — | — | — |
| Jul 23, 2025 | — | — | — | — |
| Apr 23, 2025 | — | — | — | — |
| Apr 25, 2023 | — | 1.16 | — | — |
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year
—
Next year
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 50.22M | 52.28M | 49.05M | 42.18M | 46.90M |
| Cost of revenue | 20.19M | 20.09M | 18.14M | 16.63M | 17.44M |
| Gross profit | 30.04M | 32.20M | 30.92M | 25.55M | 29.47M |
| Operating expense | |||||
| Research & development | 560,000 | 493,000 | 526,000 | 486,000 | 483,000 |
| Selling general and admin | 12.70M | 11.91M | 11.51M | 11.35M | 11.35M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 16.78M | 19.79M | 18.88M | 13.71M | 17.63M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | 3.31M | 869,000 | 181,000 | 132,000 | 252,000 |
| Pretax income | 20.09M | 20.66M | 19.06M | 13.84M | 17.88M |
| Tax provision | 3.45M | 4.19M | 4.27M | 3.04M | 3.16M |
| Net income | 16.64M | 16.47M | 14.79M | 10.80M | 14.73M |
| Basic EPS | 4.58 | 5.69 | 4.15 | 2.96 | 3.94 |
| Diluted EPS | 4.57 | 4.52 | 4.04 | 2.94 | 3.94 |
| Basic average shares | 3.63M | 3.63M | 3.66M | 3.64M | 3.74M |
| Diluted average shares | 3.63M | 3.63M | 3.66M | 3.64M | 3.74M |
| EBITDA | 20.11M | 26.21M | 26.00M | 20.81M | 24.26M |
| Net income from continuing op. | 16.64M | 16.47M | 14.79M | 10.80M | 14.73M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 135.46M | 123.87M | 115.64M | 111.75M | 109.79M |
| Current assets | |||||
| Cash | 92.87M | 75.05M | 60.97M | 51.59M | 42.79M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 92.87M | 75.05M | 60.97M | 51.59M | 42.79M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 3.49M | 5.54M | 5.29M | 4.22M | 4.84M |
| Other receivables | — | — | — | — | — |
| Inventory | 9.58M | 8.81M | 6.60M | 6.22M | 6.91M |
| Prepaid assets | — | 515,000 | 456,000 | 346,000 | 443,000 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 429,000 | 515,000 | 457,000 | 346,000 | 443,000 |
| Non current assets | |||||
| Properties | — | — | 449,000 | 377,000 | 414,000 |
| Land and improvements | 1.64M | 1.59M | 1.69M | 1.73M | 1.67M |
| Machinery furniture equipment | 17.32M | 17.07M | 16.66M | 16.75M | 16.25M |
| Construction in progress | 1.41M | 906,000 | 898,000 | 527,000 | 372,000 |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -23.72M | -22.94M | -22.80M | -22.58M | -21.87M |
| Goodwill | 32.33M | 37.09M | 45.96M | 52.32M | 58.13M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 4.95M | 10.38M | 17.76M | 23.99M | 30.21M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | — | — | — | — | — |
| Total liabilities | 7.15M | 9.62M | 8.50M | 8.92M | 8.69M |
| Current liabilities | |||||
| Accounts payable | 769,000 | 1.22M | 761,000 | 788,000 | 1.10M |
| Accrued expenses | 3.36M | 4.20M | 2.85M | 2.89M | 1.78M |
| Short term debt | — | — | — | — | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 327,000 | 337,000 | 36,000 | 3,000 | 453,000 |
| Pensions | — | — | — | — | 1.03M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 295,000 | 341,000 | 396,000 | 335,000 | 376,000 |
| Provision for risks and charges | 698,000 | 1.26M | 1.68M | 2.00M | 2.11M |
| Deferred liabilities | 1.44M | 2.06M | 2.68M | 2.80M | 2.76M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 36,000 | 36,000 | 37,000 | 36,000 | 37,000 |
| Retained earnings | 138.34M | 126.01M | 115.31M | 110.95M | 110.82M |
| Other shareholders equity | -10.66M | -12.04M | -9.05M | -8.28M | -9.78M |
| Total shareholders equity | 128.31M | 114.25M | 107.14M | 102.82M | 101.09M |
| Additional paid in capital | 594,000 | 251,000 | 841,000 | 115,000 | 18,000 |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||
| Net Income | 16.64M | 16.47M | 14.79M | 10.80M | 14.73M | 18.56M | 8.51M | 12.13M | 11.84M | 11.38M | 11.41M | 10.17M | 7.41M | 6.01M | 6.26M | 7.21M | 7.91M | 8.17M | 7.55M | 10.22M | 20.76M | 7.17M | 5.93M | 5.37M | 5.47M | 4.90M | 4.30M | 8.80M | 8.40M | 7.10M | 7.00M | 6.90M | 5.40M | 4.30M | 2.60M |
| Depreciation | 6.37M | 7.08M | 7.28M | 7.21M | 6.88M | 2.96M | 2.77M | 2.83M | 3.15M | 3.36M | 3.20M | 3.27M | 2.77M | 607,000 | 588,000 | 591,000 | 597,000 | 634,000 | 676,000 | 809,000 | 984,000 | 1.17M | 1.93M | 2.19M | 2.19M | 2.10M | 1.50M | 1.40M | 1.70M | 1.30M | 1.00M | 900,000 | 600,000 | 500,000 | 500,000 |
| Deferred Taxes | -681,000 | -395,000 | -53,000 | -19,000 | -373,000 | -277,000 | -658,000 | -484,000 | -901,000 | -500,000 | -1.40M | -600,000 | -549,000 | — | 230,000 | -46,000 | 93,000 | 118,000 | -129,000 | 75,000 | -47,000 | 108,000 | -26,000 | -13,000 | -81,000 | 100,000 | 200,000 | -100,000 | -100,000 | -100,000 | 300,000 | — | 100,000 | -100,000 | -400,000 |
| Stock-Based Compensation | 225,000 | 183,000 | 166,000 | 160,000 | 113,000 | 64,000 | 129,000 | 92,000 | 87,000 | 74,000 | 28,000 | 70,000 | 95,000 | 83,000 | 98,000 | 120,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | — | — | — | — | — | — | — | — | — | — | -3,000 | — | -1,000 | 1,000 | 7,000 | -41,000 | 65,000 | 2.62M | 933,000 | 449,000 | — | — | — | — | — | -200,000 | — | 200,000 | — | — | 100,000 | 200,000 | 200,000 | 100,000 | 100,000 |
| Accounts Receivable | 2.27M | -525,000 | -1.13M | 662,000 | -754,000 | -496,000 | -240,000 | 1.19M | 46,000 | -465,000 | -28,000 | 471,000 | 471,000 | -55,000 | 359,000 | 392,000 | -53,000 | 672,000 | -821,000 | -417,000 | 293,000 | 261,000 | 285,000 | 45,000 | 1,000 | 100,000 | 500,000 | 1.70M | -100,000 | -500,000 | -800,000 | -1.50M | -1.50M | -800,000 | -200,000 |
| Accounts Payable | -456,000 | 464,000 | -23,000 | -308,000 | 114,000 | 52,000 | 9,000 | 286,000 | -265,000 | 188,000 | -216,000 | 50,000 | -1.21M | 52,000 | -73,000 | 25,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -670,000 | -2.35M | -485,000 | 924,000 | -2.02M | -2.97M | 5.32M | -360,000 | 422,000 | -141,000 | -672,000 | 650,000 | -383,000 | 286,000 | -83,000 | -450,000 | 74,000 | -57,000 | -2.52M | 40.99M | -14.34M | -545,000 | -174,000 | 18,000 | 1.51M | 2.30M | -100,000 | -1.30M | 500,000 | 600,000 | -500,000 | -100,000 | -1.00M | -1.50M | 1.20M |
| Operating Cash Flow | 23.69M | 20.93M | 20.55M | 19.43M | 18.69M | 17.88M | 15.84M | 15.69M | 14.38M | 13.89M | 12.31M | 14.08M | 8.61M | 6.99M | 7.38M | 7.80M | 8.68M | 12.15M | 5.69M | 52.12M | 7.65M | 8.16M | 7.95M | 7.61M | 9.09M | 9.30M | 6.40M | 10.70M | 10.40M | 8.40M | 7.10M | 6.40M | 3.80M | 2.50M | 3.80M |
| Investing Activities | |||||||||||||||||||||||||||||||||||
| Capital Expenditures | — | -809,000 | -552,000 | -860,000 | -540,000 | 460,000 | -1.60M | -3.29M | -176,000 | -1.11M | -339,000 | -254,000 | -247,000 | -1.53M | -466,000 | -274,000 | 1.66M | -334,000 | -340,000 | -421,000 | -394,000 | -517,000 | -524,000 | -350,000 | -683,000 | -4.70M | -1.20M | -5.90M | -2.20M | -2.30M | -1.60M | -1.70M | -2.40M | -2.20M | -500,000 |
| Net Intangibles | — | — | — | — | -21.00M | — | — | -9,000 | -70,000 | -22,000 | -5,000 | -1,000 | -10,000 | -2,000 | -8,000 | -13,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | -41.08M | — | — | — | — | — | — | -1.01M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | — | -500,000 | -1.60M | -3.80M | -2.65M | -2.00M | -6.60M | -10.60M | -22.10M | -737,000 | — | — | — | — | — | -100,000 | -3.30M | -6.90M | -3.50M | -15.00M | -8.20M | -4.40M | -4.20M | -4.30M |
| Sale of Investments | — | — | — | — | — | 74,000 | — | — | — | — | — | 47,000 | 15.16M | 5.84M | 1.12M | 7.79M | — | 4.31M | 9.05M | 8.20M | 98,000 | — | — | — | — | — | 1.60M | 10.00M | 4.50M | 6.20M | 15.50M | 4.00M | 3.10M | 3.90M | 4.20M |
| Investing Cash Flow | — | -809,000 | -552,000 | -860,000 | -540,000 | 534,000 | -1.60M | -3.29M | -176,000 | -1.11M | -339,000 | -207,000 | -26.68M | 2.71M | -3.15M | 4.87M | -337,000 | -2.63M | -1.90M | -15.33M | -1.03M | -517,000 | -524,000 | -600,000 | -685,000 | -5.00M | -7.50M | 800,000 | -4.50M | 300,000 | -1.00M | -6.10M | -3.90M | -2.60M | -500,000 |
| Financing Activities | |||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | — | — | 26.93M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — | -4.78M | -4.04M | -3.91M | -9.09M | -5.94M | -413,000 | -463,000 | -1.92M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | — | — | — | 50,000 | 72,000 | 103,000 | 196,000 | 178,000 | 34,000 | 38,000 | 14,000 | 42,000 | 60,000 | — | 1,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | -4.28M | -5.66M | -11.47M | -11.09M | -4.51M | -5.23M | -2.96M | -6.72M | -14.01M | -12.79M | -11.30M | -22.07M | 12.14M | -6.83M | -4.23M | -15.69M | -5.21M | -7.07M | -11.02M | -10.92M | -1.91M | -10.71M | 123,000 | -11.51M | -11.96M | -1.60M | -5.20M | -14.00M | -3.10M | -8.40M | -7.30M | -300,000 | 400,000 | 200,000 | -2.20M |
| Other Cash Details | |||||||||||||||||||||||||||||||||||
| End Cash Position | 92.87M | 75.05M | 60.97M | 51.59M | 42.79M | 51.11M | 39.88M | 26.30M | 23.28M | 19.27M | 14.40M | 8.87M | 6.53M | 3.82M | 410,000 | 97,000 | 1.25M | 610,000 | 703,000 | 1.82M | 762,000 | 285,000 | 370,000 | 414,000 | 647,000 | 1.40M | 1.00M | — | — | — | — | — | — | — | — |
| Income Tax Paid | 4.83M | 4.97M | 4.62M | 3.19M | 5.30M | 4.85M | 5.15M | 4.85M | 5.34M | 3.09M | 3.97M | 4.42M | 2.69M | 2.81M | 3.08M | 3.36M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | 65,000 | 296,000 | 439,000 | 658,000 | 860,000 | 25,000 | 51,000 | 198,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 21.64M | 20.33M | 20.65M | 19.28M | -4.48M | 16.43M | 15.31M | 11.23M | 13.56M | 14.26M | 11.96M | 13.31M | 11.11M | 5.62M | 6.75M | 7.48M | 7.11M | 10.52M | 6.11M | 27.04M | 7.94M | 8.14M | 7.34M | 7.46M | 8.42M | 4.80M | 3.80M | 5.30M | 8.90M | 6.50M | 5.80M | 4.60M | 1.50M | 200,000 | 3.80M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 108,096 | 6.49M | 3.19% |
| Fidelity Low-Priced Stock Fund | Oct 31, 2024 | 64,304 | 3.86M | 1.90% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 61,708 | 3.70M | 1.82% |
| JP Morgan Small Cap Blend Fund | Sep 30, 2024 | 56,125 | 3.37M | 1.65% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 48,796 | 2.93M | 1.44% |
| DFA U.S. Micro Cap Series | Oct 31, 2024 | 46,317 | 2.78M | 1.37% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 33,353 | 2.00M | 0.98% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 32,629 | 1.96M | 0.96% |
| Fidelity Small Cap Discovery Fund | Oct 31, 2024 | 30,003 | 1.80M | 0.88% |
| DFA U.S. Small Cap Series | Oct 31, 2024 | 27,369 | 1.64M | 0.81% |
Article
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Feb 4, 2025
Article
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
Jan 31, 2025
Article
UTMD Reports Year 2024 and Fourth Quarter Financial Performance
SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.
Jan 28, 2025
